Publications by authors named "Allison Sigmund"
Article Synopsis
- The Omicron variant of COVID-19, which began in 2022, evolved from several lineages (BA.1, BA.2, BA.5) and developed mutations that help it evade neutralizing antibodies.
- Researchers evaluated the effectiveness of antibody responses by tracking over 420,000 U.S. plasma donors and studying blood samples from vaccinated and recovered individuals, along with testing clinically approved therapies.
- Findings indicated that antibody responses improved over time, but emerging variants like BQ.1.1 and XBF were increasingly resistant to treatments like Evusheld and Sotrovimab, suggesting that even dominant variants can evade antibodies while maintaining a persistent advantage in spreading.
